supplementary material – Page 223 – Communicable Diseases Research

The Epidemiology and Predictors of Outcomes Among Confirmed COVID-19 Cases in a Large Community Healthcare System in South Florida

Original Paper

Published on 2021-01-072022-10-29
Journal: Journal of community health [Category] COVID-19, MERS, SARS,

Sex differences and psychological stress: responses to the COVID-19 pandemic in China

Research Article

Published on 2021-01-072022-10-28
Journal: BMC Public Health [Category] Coronavirus,

[키워드] age age and gender basic China Chinese concerning condition conditions Contact convenience sampling COVID-19 COVID-19 knowledge COVID-19 outbreak COVID-19 pandemic COVID-19 patient cross-sectional demographic characteristics Diseases Effect effort emotional employment Factor female Fever Future Health Impact investigated male media men and women Mental observation physical platform Psychological psychological health psychological resilience Psychological stress psychological support public health crisis public health threat questionnaire Reactions Region Resilience respond response Result risk risk of infection Sex Sex difference sex differences significantly Spread Stress stressors supplementary material Support threat WeChat were measured
[DOI] 10.1186/s12889-020-10085-w PMC 바로가기 [Article Type] Research Article

Incorporating and addressing testing bias within estimates of epidemic dynamics for SARS-CoV-2

SARS-CoV-2에 대한 전염병 역학 추정치 내에서 테스트 편향 통합 및 해결

Research Article

Published on 2021-01-072022-09-01
Journal: BMC Medical Research Methodology [Category] Fulltext, MERS, 진단,

[키워드] Affect biases calculate calculated compartment model compartmental model confirmed case confirmed cases Covid-19, inaccurate epidemic predictions, overestimation of COVID death rate death rates deaths dependence different time point different time points disease disease manifestation Effect Epidemic Epidemiology estimate estimates estimation expected explicit fatality Fatality rate favor Infection mitigate Model Patient predict Randomized Result sample sizes sampling Sampling bias SARS-CoV-2 Serological testing significantly small sample size statistically significant supplementary material systematic errors unbiased estimates
[DOI] 10.1186/s12874-020-01196-4 PMC 바로가기 [Article Type] Research Article

Implementation of podiatry telephone appointments for people with rheumatic and musculoskeletal diseases

Research

Published on 2021-01-072022-10-30
Journal: Journal of Foot and Ankle Research [Category] Coronavirus,

Misinformation about COVID-19: evidence for differential latent profiles and a strong association with trust in science

Research Article

Published on 2021-01-072022-10-28
Journal: BMC Public Health [Category] COVID-19,

Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil

Research

Published on 2021-01-062022-10-30
Journal: Journal of Mathematics in Industry [Category] COVID-19,

[키워드] Affect affecting Brazil chose clinical study connection coronavirus country COVID-19 COVID-19 pandemic feature flattening lifted lockdown measure Neural network processed quarantine robust SEIR SEIR models Spread supplementary material virus was done
[DOI] 10.1186/s13362-020-00098-w PMC 바로가기 [Article Type] Research

Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo

Research Article

Published on 2021-01-062022-10-28
Journal: BMC Public Health [Category] COVID-19, MERS,

Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial

COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-062022-09-10
Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제,

[키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter

Rapid single cell evaluation of human disease and disorder targets using REVEAL: SingleCell™

Database

Published on 2021-01-062022-10-28
Journal: BMC Genomics [Category] COVID-19,

[키워드] ACE2 Array native database Atla caused Cell cell type annotation cells cellular co-expression complex coronavirus COVID-19 COVID-19 pandemic Data storage and retrieval database dataset datasets described develop diagnostics disorder evaluate evaluated Evaluating exacerbated example explain expressed expressing expression expression profile facilitate Gene Expression Genes Hierarchical Human human cell human disease hypothese hypotheses include individual cell infected patient Infection infections Infectious disease Information extraction involved less manuscript Metadata Multiple studies oncology Ontology organs platform populations Precision prevalent Protein question Rapid resource returned SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 research SARS-CoV-2 virus SciDB selected Sequencing Single Cell Single cell analysis single-cell single-cell dataset spread of COVID-19 supplementary material target target gene targets threshold tissue TMPRSS2 utility Vaccine viral entry virulence virus worldwide pandemic
[DOI] 10.1186/s12864-020-07300-8 PMC 바로가기 [Article Type] Database

A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)

Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)

Letter

Published on 2021-01-062022-08-31
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website
[DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter